Muscle Is Becoming Medicine’s Most Underused Vital Sign
Across five papers spanning longevity frameworks, muscle power, structured exercise, handgrip strength, and cellular senescence, one signal repeats: neuromuscular function is now one of the most precise, low-cost predictors of mortality and functional decline available in clinical medicine. The clinical evidence for measuring and training it is mature. The infrastructure to measure it routinely, reimburse for it, and act on it in a standard visit is not. Monday sets the frame, Tuesday and Wednesday build the mechanistic and functional case, Thursday tests it against real-world feasibility, and Friday unifies all four at the cellular level and names the systemic gap.
MONDAY
The Longevity Pyramid Has a Foundation Problem - and It Isn’t the One You’d Expect
Health systems have spent the past decade building longevity programs around diagnostics - genetic panels, epigenetic clocks, and biomarker dashboards. A 2024 Frontiers in Aging review reframes the hierarchy: diagnostics sit at the base of a five-tier “Longevity Pyramid,” but the intervention with the largest, most consistently reproducible effect size in the entire model isn’t a test or a supplement. It’s exercise. Specifically, the structured, dosed, prescribable exercise that physical therapy already delivers at scale - and that most longevity strategy documents treat as a lifestyle footnote rather than tier-one infrastructure.
By the Numbers:
High cardiorespiratory fitness: 73% lower cardiovascular mortality, 58% lower all-cause mortality
Resistance training: 43% reduction in Alzheimer’s risk, 33% reduction in mild cognitive impairment
WHO threshold reaffirmed as the evidence floor: 150–300 min/week moderate or 75–150 min/week vigorous activity
No single diagnostic test can establish biological age - the review is explicit that multi-modal measurement (bloodwork, epigenetics, wearables, physiological testing) is required, and even then functions only as a baseline, not a verdict.
Why the pyramid gets the order right, but health systems get the emphasis backward
The Longevity Pyramid’s five tiers - diagnostics, lifestyle, supplements, pharmacological/non-pharmacological tools, and experimental strategies - are explicitly sequential: each tier is intended to build on the one below it. In practice, most employer wellness programs and executive health packages invert this. They lead with diagnostics and pharmacology (biomarker panels, NAD+ protocols, peptide therapies) because those are billable, marketable, and easy to package. Exercise prescription - tier two, and the tier with the strongest and cheapest evidence base - gets delegated to a generic “stay active” recommendation with no dosing, no progression, and no clinician accountable for outcomes.
The equity and evidence gaps the authors don’t let readers skip past.
The review is candid about its own limits: long-term human RCTs across the pyramid’s upper tiers are lacking, individual response variation is wide, and several tier 3–5 interventions (senolytics, IV therapy, experimental gene-editing approaches) are functionally accessible only to patients who can pay out of pocket. That’s a meaningful caveat for any health system considering a “longevity service line” - the most defensible, reimbursable, equity-neutral tier is also the one furthest from where current investment is going.
“No single test can precisely assess biological age” - which means a longevity strategy built primarily around diagnostics is building on the pyramid’s least conclusive tier, not its most.
Strategic Takeaways by Role
PT Clinicians: Your scope of practice already delivers the pyramid’s highest-evidence tier. Frame plans of care explicitly around longevity/healthspan outcomes, not just symptom resolution - the data supports it.
Clinical Leaders: Audit whether your organization’s “longevity” or “healthy aging” service lines lead with diagnostics/pharma or with dosed exercise prescription. The evidence hierarchy and the investment hierarchy are currently inverted.
Health System Executives: Tier-two interventions (structured exercise) are the cheapest to scale and the most defensible clinically - a stronger ROI case than diagnostic-panel-led longevity programs before you build the latter.
Payers: Reimbursement models still treat exercise prescription as a wellness benefit rather than a mortality-modifying clinical intervention with effect sizes exceeding many covered pharmacologic therapies.
Policymakers: Equitable access to tier 2 (lifestyle) interventions should be the policy floor before tier 3–5 (supplement/experimental) access questions are addressed - the review flags this explicitly as an ethics gap.
Researchers: Long-term RCT data across pyramid tiers 3–5 remains the field’s biggest evidence gap; tier 2 has the deepest evidence base but the least novel research attention.
EMR/IT Developers: Longevity-adjacent care pathways need structured fields for exercise dosing and progression, not just biomarker results - most current EHR longevity modules are diagnostics-first by design.
Citation: Martinović, A., Mantovani, M., Trpchevska, N., Novak, E., Milev, N. B., Bode, L., Ewald, C. Y., Bischof, E., Reichmuth, T., Lapides, R., Navarini, A., Saravi, B., & Roider, E. (2024). Climbing the longevity pyramid: Overview of evidence-driven healthcare prevention strategies for human longevity. Frontiers in Aging, 5, 1495029. https://doi.org/10.3389/fragi.2024.1495029
Audience tags: #LongevityMedicine #ValueBasedCare #ClinicalLeadership #HealthPolicy
Quick summary: The longevity field’s strongest evidence sits at its most neglected investment tier.
The Need for Speed: Why Muscle Power, Not Strength, May Be the Better Mortality Signal
Hook: Cardiorespiratory fitness has held the top spot in survival medicine for decades, and for good reason. But a 2025 Mayo Clinic Proceedings editorial makes the case that the field has been under-measuring a more sensitive predictor sitting one layer beneath it: muscle power. Drawing on a 3,899-adult cohort with a median follow-up of nearly 11 years, the authors show that relative muscle power - not relative strength - is the stronger signal of who is, and isn't, going to survive the next decade. That distinction matters clinically, because most current strength-based screening and sarcopenia definitions aren't built to catch it.
By the Numbers:
CLINIMEX cohort: 3,899 adults, median follow-up 10.8 years
Relative muscle power (rPOW) hazard ratios: 5.88 (men), 6.90 (women)
Relative strength (rSTR) hazard ratios by comparison: 1.62 (men), 1.71 (women) - roughly 3–4x lower
Current sarcopenia definitions: exclude power as a criterion entirely
Why velocity, not just force, is the variable to watch Power is force multiplied by velocity, and aging erodes the velocity component faster and earlier than it erodes maximal force. That has a direct clinical translation: the tasks most tied to independence and fall risk - rising from a chair, climbing a flight of stairs, catching yourself before a fall - depend on how quickly muscle can generate force, not just how much force it can eventually produce. A patient can retain reasonably preserved maximal strength on a manual muscle test while their power output - and their real-world functional margin - has already declined substantially.
A sarcopenia framework that may be measuring the wrong half of the equation The editorial's most direct challenge to current practice: sarcopenia definitions built around strength and lean mass may be missing the variable most tied to survival. The authors are explicit that this isn't a minor refinement - a definition that excludes power risks under-identifying patients who are, by the mortality data, at meaningfully elevated risk. That's a real gap for any clinical pathway using current sarcopenia criteria as a triage or referral trigger.
"rPOW was a significantly stronger predictor of all-cause mortality than rSTR" - a finding that argues for adding power testing, not substituting it for existing strength assessment.
Strategic Takeaways by Role
PT Clinicians: Strength testing alone may be under-detecting your highest-risk patients. Where feasible, incorporate power-based measures (e.g., timed sit-to-stand, countermovement jump variants) alongside standard strength assessment.
Clinical Leaders: If your sarcopenia or falls-risk screening pathway is built on strength/lean-mass criteria alone, this data is a direct prompt to review whether power is being captured anywhere in that pathway.
Health System Executives: No widely available clinical tool for rPOW exists yet - an open-market gap for whichever health system or vendor builds the first standardized, scalable power-assessment protocol.
Payers: Hazard ratios in the 6–7x range are a stronger risk-stratification signal than many currently reimbursed screening tools - worth tracking as power-based assessments mature toward clinical standardization.
Policymakers: Sarcopenia is a recognized diagnostic category in several care and coverage frameworks; this data is an evidence-based argument for revisiting whether those definitions should formally incorporate power.
Researchers: The editorial names its own gaps clearly - CRF and physical activity weren't adjusted for, lean mass wasn't directly measured, and no widely available clinical rPOW tool exists. All three are open, fundable research questions.
EMR/IT Developers: If power-based testing moves toward standard-of-care, structured fields distinct from existing strength/grip fields will be needed - treating power as a strength subcategory would blur exactly the distinction this data depends on.
Citation: Carbone, S., & Alonso, W. W. (2025). The need for speed: Improving muscle power for longevity. Mayo Clinic Proceedings, 100(8), 1281–1284. https://doi.org/10.1016/j.mayocp.2025.06.011
Audience tags: #MuscleHealth #SarcopeniaScreening #MortalityRisk #ClinicalMeasurement
Quick summary: Muscle power beats muscle strength as a mortality predictor by a factor of three to four - and current screening tools mostly aren't built to catch it.
WEDNESDAY
Exercise Prescription for Older Adults Isn’t a Lifestyle Recommendation - It’s a Dosed Clinical Intervention
A 2026 narrative review in Aging Advances makes a claim that should reframe how health systems talk about exercise for patients over 65: it isn’t advice, it’s therapy with a defined mechanism, a dose-response curve, and measurable biological targets. The review ties structured exercise to reversal or attenuation of nearly every hallmark of physiological aging - sarcopenia, declining VO2max, bone loss, immune decline - through specific, named molecular pathways. That’s a materially different claim than “patients should move more,” and it has direct implications for how PT-led exercise programs get positioned, staffed, and billed.
By the Numbers:
Strength training: 25–35% strength gains, 10–15% muscle mass increases - reproducible even in nonagenarians
Balance training: 20–40% reduction in fall risk
Multicomponent training: 35% functional improvement in frail adults over 12 weeks
Supervised programs: 60% reduction in injury risk versus unsupervised exercise
Baseline injury rate for moderate exercise in this population: just 1–3 per 1,000 hours, mostly minor
The mechanism case: this isn’t just “activity,” it’s targeted molecular signaling
The review traces exercise’s effects through named pathways - mTORC1 activation and myokine release (IL-6, irisin, BDNF) in muscle; AMPK/SIRT1/PGC-1α activation for mitochondrial biogenesis; VEGF-mediated angiogenesis in the vasculature. This is the language of geroscience, not general wellness, and it’s the strongest argument available for positioning exercise prescription as a covered clinical service with the same rigor as a pharmacologic intervention: a defined mechanism, a dose, a monitored response.
The prescription itself is more specific than most current protocols.
The review’s recommended prescription - ≥150 min/week moderate aerobic activity, strength training 2–3x/week at ~60% 1RM, balance training ≥2x/week, flexibility ≥2x/week - is multicomponent by design, and the evidence shows multicomponent programs outperform single-modality ones. Most current outpatient plans of care and community “senior fitness” offerings deliver one or two of these four components, not all four in the doses shown to work.
“One of the most cost-effective interventions to extend healthspan, reduce healthcare burden, and promote active aging worldwide” - a claim that sits uneasily next to how thinly exercise-based care is currently reimbursed relative to pharmacologic alternatives with narrower effect sizes.
Strategic Takeaways by Role
PT Clinicians: Multicomponent programming (aerobic + strength + balance + flexibility) outperforms single-modality plans - an argument for broadening standard plans of care rather than defaulting to strength-only or balance-only protocols.
Clinical Leaders: Supervision cuts injury risk by more than half; unsupervised “home exercise program only” models may be under-delivering on both safety and outcomes for frail patients.
Health System Executives: The cost-effectiveness claim here is a direct input for any healthspan or falls-prevention business case - pair it with your utilization and readmission data before pitching investment.
Payers: A 35% functional improvement in frail adults in 12 weeks is a strong utilization-offset argument for expanding covered visit counts for multicomponent PT-led programs in this population.
Policymakers: Access barriers named in the review - fear of injury, pain, lack of support - are largely structural (supervision availability, program funding), not motivational; policy framed around “encouraging activity” misses the actual barrier.
Researchers: Exercise mimetics, XR-based training, and AI-personalized prescription are flagged as open frontiers - an underexplored intersection with existing PT delivery models.
EMR/IT Developers: Validated functional assessment tools (SPPB, six-minute walk test) referenced here should be structured, trackable fields, not free-text notes, if outcomes are going to support the ROI case above.
Citation: Puche, J. E. (2026). Exercise and aging: Unlocking health beyond 65 years old. Aging Advances, 3(2), 1–15. https://doi.org/10.4103/AGINGADV.AGINGADV-D-25-00036
Audience tags: #GeriatricCare #ExerciseIsMedicine #FallsPrevention #PTValue
Quick summary: Exercise for older adults has a dose-response curve as defined as any drug - it just isn’t billed like one.
THURSDAY
Handgrip Strength Is the Cheapest Biomarker in Sports and Geriatric Medicine - So Why Is the Research Still This Fragmented?
A 2026 bibliometric review in Sports mapped 229 publications on handgrip strength (HGS) and found a field growing exponentially - output quadrupled between 2018 and 2021 - but structurally scattered: no standardized testing protocol, thin coverage of training interventions, and inconsistent predictive value across populations. That’s a notable gap for a measure this cheap and this fast to administer. HGS costs almost nothing, takes under a minute, and correlates with outcomes ranging from sprint performance in youth athletes to frailty and mortality risk in older adults - yet it still isn’t a standardized vital sign in either sports medicine or primary/geriatric care.
By the Numbers:
Publication growth: from under 10 papers/year (2011–2018) to 37 papers in 2024 - R² = 89% on the exponential trend
HGS + age explained 67% of sprint variance and 61% of jump variance in youth soccer athletes
8 core journals identified via Bradford’s law; U.S. and Spain lead global citation output (614 and 581, respectively)
Context-dependency flagged explicitly: HGS did not predict competitive success in female judokas - a reminder that a strong general biomarker isn’t a universal one.
A validated, low-cost signal without a validated, universal protocol
The review’s core tension is this: HGS is consistently associated with major muscle group strength, aerobic capacity, and body composition across a wide range of sports and age groups, which is exactly what makes it attractive as a scalable screening tool. But the authors found no standardized testing protocol across the 229 studies reviewed - device type, hand position, number of trials, and population norms vary enough that cross-study and cross-setting comparison is limited. A biomarker this accessible shouldn’t still be this inconsistent operationally.
The gap that matters most for delivery systems, not just researchers
Training-intervention studies - i.e., research on how to improve HGS and whether doing so changes downstream outcomes - are sparse relative to the volume of studies establishing HGS as a correlate or predictor. That’s the same pattern seen in Tuesday’s muscle power findings: strong predictive evidence, thin intervention evidence. For a health system deciding whether to add HGS to a standard geriatric or sports-medicine intake, the honest answer is that it’s a good screen with an underbuilt “what do we do about it” pathway.
Morphological factors - hand size, finger length, forearm circumference - significantly influence raw HGS values, which cautions against using single-cutoff norms without population-specific calibration.
Strategic Takeaways by Role
PT Clinicians: HGS is a fast, low-cost adjunct screen, but treat single-cutoff norms cautiously - morphological and sport/population context materially affect interpretation.
Clinical Leaders: Before standardizing HGS into intake workflows, confirm which protocol (device, position, trial count) your teams are using - cross-clinic consistency is not guaranteed by the current literature.
Health System Executives: HGS is close to a zero-marginal-cost screening tool; the business case is strong for adoption, weak for claiming it alone changes care pathways without a defined intervention protocol behind it.
Payers: A near-costless predictive screen is an appealing utilization-management input, but the evidence base for what action to take on an abnormal result is thinner than the evidence for the measurement itself.
Policymakers: Standardized protocol adoption (device, method, population norms) is a low-cost, high-leverage policy lever that individual health systems are unlikely to solve on their own.
Researchers: The clearest open lane identified in the review is HGS training-intervention research tied to functional and sport-specific outcomes - the correlational evidence is already saturated.
EMR/IT Developers: If HGS is added to intake templates, the protocol metadata (device, hand, trial number, population norm used) needs to be captured alongside the value itself, or the data won’t be comparable across time or sites.
Citación: García-Carrillo, E., Salas-Gómez, D., Castillo-Paredes, A., Becerra-Patino, B. A., Farías-Valenzuela, C., Cortés-Roco, G., Alarcón-Rivera, M., Fuentes-Barría, H., & Yáñez-Sepúlveda, R. (2026). Mapping handgrip strength research in sports performance: A bibliometric review of applications, trends, and future directions. Sports, 14(3), 101. https://doi.org/10.3390/sports14030101
Audience tags: #ClinicalMeasurement #SportsMedicine #GeriatricScreening #EMROptimization
Quick summary: The cheapest strength biomarker in medicine still doesn’t have a standardized protocol.
FRIDAY - Weekly Synthesis
Why Your Muscles Are Aging Faster Than Your Charts Suggest: Senescence as the Mechanism Underneath Every Story This Week
Every finding this week - the power-mortality link, the exercise-driven molecular pathways, the handgrip-frailty association - has a shared cellular mechanism underneath it: senescence. This week’s final source, a review of cellular senescence across organ systems, argues that senescent cells and their inflammatory secretions (SASP - senescence-associated secretory phenotype) are the common driver connecting sarcopenia, cardiovascular aging, and cognitive decline. It’s the mechanistic thread this week’s four other papers describe from the outside - mortality risk, functional decline, screening gaps - without naming the cellular process producing them.
By the Numbers:
Senescence contributes to measurable decline across at least three organ systems reviewed in detail: cardiovascular, musculoskeletal, and nervous system.
SASP-driven signaling operates through named inflammatory mediators (IL-1, IL-6, IL-8, TNF-α, TGF-β) with direct links to frailty and multimorbidity.
Two therapeutic classes are in active development: senolytics (eliminate senescent cells) and senomorphics (suppress SASP without eliminating the cell) - human translation described as early but promising.
Exercise and nutrition are named as the most validated senescence-modulating interventions currently available - connecting directly back to Tuesday and Wednesday’s findings.
The mechanistic bridge between this week’s four other papers
Monday’s Longevity Pyramid treats lifestyle intervention as tier two of five. Tuesday’s power data shows why strength alone under-predicts mortality risk. Wednesday’s exercise review names the molecular pathways (AMPK/SIRT1/PGC-1α) that this senescence review identifies as senescence-modulating. Thursday’s handgrip data is, in effect, a surface-level readout of the same satellite-cell exhaustion and muscle protein degradation this review describes as senescence-driven sarcopenia. None of the earlier four papers named senescence explicitly - but each was measuring or intervening on a downstream consequence of it.
The systemic gap: intrinsic capacity as a clinical construct doesn’t yet have clinical infrastructure.
The review ties senescence directly to the WHO constructs of frailty and intrinsic capacity - locomotion, cognition, vitality, sensory function, psychological resilience. These are recognized geriatric frameworks, but they still don’t map cleanly onto standard EHR fields, billing codes, or single-visit assessment protocols the way a lab value does. The week’s throughline lands here: the science has converged on muscle function and cellular senescence as unifying, measurable, modifiable predictors of healthspan. The clinical, financial, and technical infrastructure to screen for it, document it, bill for it, and act on it as routinely as blood pressure has not caught up.
The authors’ central claim: senescence is “a modifiable biological process,” and lifestyle intervention - not pharmacology first - remains the most validated lever available today.
Strategic Takeaways by Role
PT Clinicians: Your interventions (resistance training, multicomponent exercise) are directly senescence-modulating per this review - that’s a stronger clinical rationale than “improves strength” for framing plans of care around healthspan outcomes.
Clinical Leaders: Frailty and intrinsic capacity assessments are the natural intake layer connecting this week’s biomarkers (power, grip, functional testing) - worth auditing whether your current geriatric intake captures any of them structurally.
Health System Executives: Senotherapeutics are still early-stage; the defensible near-term investment is scaling the senescence-modulating interventions already proven - structured exercise - not waiting on pharmacology.
Payers: Frailty and intrinsic capacity remain under-coded relative to their predictive value; coverage policy built around discrete diagnoses may be missing the functional-decline signal this week’s data consistently points to.
Policymakers: WHO’s intrinsic capacity framework offers a ready-made structure for national or system-level healthy-aging metrics - better aligned with this week’s evidence than diagnosis-count-based aging metrics.
Researchers: Human translational data on senotherapeutics remains the field’s biggest gap - mirroring the tier 3–5 evidence gap flagged in Monday’s Longevity Pyramid review.
EMR/IT Developers: None of this week’s five constructs - power, grip, multicomponent exercise dosing, frailty, intrinsic capacity - have a consistent structured field across common EHR platforms; that’s the connective infrastructure gap this week’s clinical evidence is outrunning.
Audience tags: #CellularSenescence #HealthspanStrategy #FrailtyCare #WeeklySynthesis
Quick summary: This week’s biomarkers all point to the same cellular mechanism - and to infrastructure that hasn’t caught up to it.
Five papers, one signal: muscle function is not a peripheral wellness metric - it is one of the most precise, low-cost, and modifiable predictors of mortality and functional decline available in medicine today. The Longevity Pyramid places lifestyle intervention beneath diagnostics in build order but above it in evidence strength. Muscle power outpredicts strength by a wide margin. Structured, multicomponent exercise reverses named molecular pathways of aging. Handgrip strength delivers nearly all of this predictive value for the cost of a dynamometer and sixty seconds. And underneath all four, cellular senescence - modifiable, exercise-responsive, and still absent from most structured clinical documentation - is the mechanism tying them together. The evidence base for measuring and acting on neuromuscular aging is arguably more mature than the evidence base for several diagnostics currently marketed as longevity medicine’s cutting edge. The infrastructure gap isn’t scientific. It’s operational: no standardized protocol, no consistent EHR field, no billing code that reflects what the data has already shown.
